Beta Drugs Ltd. · NSE:BETA
Beta Drugs — H1 FY27 Earnings Presentation
23 slides from Beta Drugs's earnings presentation, Oct 22, 2026
Slide 1: H1 FY27 Financial Results
H1 FY27 Financial Results Oct 2026
Slide 2: Disclaimer
Disclaimer • This corporate presentation has been prepared by Beta Drugs Limited (the “Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. • This presentation should not be construed as legal, tax,
Slide 3: Beta: Evolution into a Global Special Formulations Company
BETA: EVOLUTION INTO A GLOBAL SPECIAL FORMULATIONS COMPANY
Slide 4: Beta – On Path to a Global Specialty Pharmaceutical Powerhouse
BETA – ON PATH TO A GLOBAL SPECIALTY PHARMACEUTICAL POWERHOUSE 2014-17 2017-20 2021-24 2024-27 2027-30 Revenue (INR) 70 Crs. ~100 Crs. ~300 Crs. >500 Crs. ~1,000 Crs. Fast growing Branded One of the leading domestic Scaled-up fastest growing Established presence in Global specialty segment and entry
Slide 5: Beta's Blueprint for Building Enduring Legacy of Brands
BETA’s BLUEPRINT FOR BUILDING ENDURING LEGACY OF BRANDS Novel Formulations Brand Building Depth of Coverage Integrated Manufacturing 7 Brands with > INR 5Crs.+ sales Integrated Manufacturing Setup PATIENT COMPLIANCE Growth of Top Brands 46% Beta Drugs Ltd. Adley Adley Lab Ltd. 1st-in-India oral form
Slide 6: World Class Manufacturing and R&D – Backbone of Global Expansion Strategy
WORLD CLASS MANUFACTURING AND R&D – BACKBONE OF BETA’s GLOBAL EXPANSION STRATEGY Beta Drugs Limited Adley Formulations Pvt. Ltd. Adley Lab Ltd. Formulation manufacturing facility Formulation manufacturing facility API manufacturing facility Rigorous R&D process to develop novel formulations Leading
Slide 7: Our Key Enablers for Sustained Profitable Growth
OUR KEY ENABLERS FOR SUSTAINED PROFITABLE GROWTH Key Parameters Strategic Focus KRA H1FY27 Performance ■ Gross Margins Cost Efficiencies ■ EBITDA Margins R&D Investments ■ New Product Launches Product Registrations ■ Dossier submissions Attracting and Retaining ■ Attrition rate Talent 7 Privileged &
Slide 8: H1 FY27: Financial Performance
H1 FY27: FINANCIAL PERFORMANCE
Slide 9: H1 FY27 – Characterized by Rising Uncertainty in Global Markets
H1 FY27 - CHARACTERIZED BY RISING UNCERTAINTY IN GLOBAL MARKETS Average Brent Crude (US$/ barrel) 97.5 Soaring Crude Prices 68.8 +41.7% Rose from US$ 68.8/bbl to US$ 97.5 /bbl in H1’FY27 H1 FY26 H1 FY27 US 10 –Year Treasury Yield: average (%) 4.59 Rising Interest Rates +29 bps US Treasury yields ros
Slide 10: Beta Has Demonstrated Significant Resilience Amidst Challenging Global Macros
BETA HAS DEMONSTRATED SIGNIFICANT RESILIENCE AMIDST CHALLENGING GLOBAL MACROS Delivered robust topline growth… 300 40% Sustained growth across key business segments with Revenue % Growth Branded Oncology growing at 17% in H1FY27 27.6% 29.2% 30% 200 20% 12.9% 263 100 180 204 10% Gross Margins rose to
Slide 11: Beta on Track to Accomplish Vision 2030
BETA ON TRACK TO ACCOMPLISH VISION 2030 H1 FY27 Revenue Key Highlights for H1 FY27 Other 6% Branded Deeper penetration in key accounts/hospitals FY’21 +Export CMO 44% Branded 71 Crs. Healthy pipeline that continues to drive sales 50% Products Top 10 brands contributed ~50% to total topline Well entr
Slide 12: H1 FY27: Segment Analysis
H1 FY27: SEGMENT ANALYSIS 12 Privileged & Confidential, © 2026, All Rights Reserved.
Slide 13: Branded Onco Segment: Strong Execution Drives Sustained Growth
BRANDED ONCO SEGMENT: STRONG EXECUTION DRIVES SUSTAINED GROWTH Delivering consistent robust growth Key Highlights - Branded Oncology Revenue growth of 17% to ~INR 71 Crs. 71 Oncology OSDs contribution grew to ~50% - brand building initiative playing out 60 Empanelled with the prestigious Tata Memori
Slide 14: Focus on Innovation to Drive Differentiation
FOCUS ON INNOVATION TO DRIVE DIFFERENTIATION Enduring velocity of new product launches Strong Product Pipeline Top 15 brands 19 17 New launches FY21 - FY 23 FY24 - H1 FY27 Novel formulations – hallmark of our innovation H1 FY27 – Key Launches 2027 PEG-ADRIB 14 14 Privileged & Confidential, © 2026, A
Slide 15: Nivian – Focused Brand Building Driving Accelerated Growth
NIVIAN – FOCUSED BRAND BUILDING DRIVING ACCELERATED GROWTH ------------------------------------------------------------ Strong growth on the back of increased penetration Building a formidable branded franchise 75% 31 Top 5 brand 18 sales, 63% H1 FY26 H1 FY27 % Growth Increasing acceptance with corp
Slide 16: Derma: Perched on a Strong Foundation for Future Growth
DERMA: PERCHED ON A STRONG FOUNDATION FOR FUTURE GROWTH Global licencing – strengthening market position in Cosmeceuticals Strong trajectory in secondary sales 1,068 823 Agreement for the “First to Exclusive agreement with launch” product for Mesotherapy Frezyderm for India to market in Indian Cosme
Slide 17: Export Formulations – Steady Progress in Product Filings
EXPORT FORMULATIONS – STEADY PROGRESS IN PRODUCT FILINGS Geographical split (H1FY27) 415 registrations CIS ASIA 180 4% 17% 150 MENA 49% No of LATAM registrations 59 AFRICA till H1’27 26 17% 13% LatAm APAC MENA AFRICA Total Sales – INR 43 Crs. 35 new approvals in Columbia, Peru, Jordan, Ethiopia, 872
Slide 18: CMO Business on Track to Deliver Record Growth with Improving Margins
CMO BUSINESS ON TRACK TO DELIVER RECORD GROWTH WITH IMPROVING MARGINS Strong Growth in CMO aided by Marquee customers added in H1 95 Trusted 79 Partners Established supplier to leading Indian pharma companies Sustained H1 FY26 H1 FY27 growth H1FY27 characterized by expanding supply relationships whi
Slide 19: API: Expansion into Export Markets Anchored Around Backward Integration
API: EXPANSION INTO EXPORT MARKETS ANCHORED AROUND BACKWARD INTEGRATION Expanding portfolio of 80% Facility geared to meet API products formulations with in- regulated market house API manufacturing accreditations API – a key source of competitive advantage Healthy growth in API business with signif
Slide 20: Balance Sheet
FY26: BALANCE SHEET 20 Privileged & Confidential, © 2026, All Rights Reserved.
Slide 21: Balance Sheet
BALANCE SHEET H1’25 H1’26 H1’27 (Rs Cr) (Rs Cr) (Rs Cr) Equity Share Capital 181 221 475 Borrowing (Long term & 19 146 49 short term) Other liabilities 95 121 133 Total liabilities 295 488 656 Fixed asset 66 112 229 (Net of depreciation) Cash & cash equivalent 28 123 104 Other assets 201 254 323 Tot
Slide 22: Financial Ratios – Continuous Improvement in All Operating Metrics
FINACIAL RATIOS – CONTINUOUS IMPROVEMENT IN ALL OPERATING METRICES -------------------------------------- ROCE (%) Gross Margin (%) 56.2% 30% 25% 23.3% 20.1% 19.9% 20% 52.8% 51.4% 15% 10% 5% 0% H1 FY25 H1 FY26 H1 FY27 H1 FY25 H1 FY26 H1 FY27 ----------------------------------------------------------
Slide 23: Thank You
THANK YOU Head office: SCO 184, Sector 5 Panchkula 134114 Haryana (India) Website: www.betadrugslimited.com Email: [email protected] 23 Privileged & Confidential, © 2026, All Rights Reserved.